ADVFN - Advanced Financial Network.
HOME» NASDAQ » H » HGSI Stock Price » HGSI Stock News

Human Genome Sciences Share News

 Human Genome Sciences (mm) Stock Price
HGSI Stock Price
 Human Genome Sciences (mm) Stock Chart
HGSI Stock Chart
 Human Genome Sciences (mm) Stock News
HGSI Stock News
 Human Genome Sciences (mm) Company Information
HGSI Company Information
 Human Genome Sciences (mm) Stock Trades
HGSI Stock Trades

Human Genome Holder Says Glaxo Bid "Unacceptable" - Newspaper

LONDON -(Dow Jones)- A fund with a 5.6% stake in Human Genome Sciences Inc. (HGSI), the U.S. drug company for which GlaxoSmithKline PLC (GSK.LN) has made an unsolicited $2.6 billion offer, said the approach is "unacceptable", according to the Sunday Times. Human Genome Sciences, based in Rockville, Md., on April 20 rejected Glaxo's $13 a share offer, which it said undervalues the company. Taube Hodson Stonex, a London-based fund, said the offer amounted to Glaxo trying to "get a steal with an offer that completely undervalues the company", the Sunday Times reports, attributing the remarks to Taube Hodson Stonex's Mark Evans. "Towards $20 per share would still feel undervalued," Evans is quoted as saying. THS couldn't be reached for comment Sunday. Glaxo and Human Genome Sciences have a long working relationship, co-leveloping and sharing profits on Benlysta, a lupus medicine. Newspaper Web site: -London Bureau, Dow Jones Newswires; +44 (0)20 7842 9320

Stock News for Human Genome Sciences (HGSI)
No Recent News Available

Human Genome Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations